Characterisation of the clinical features and disease progression of patients with retinal degenerative disease over 5 years and correlation with biomarkers in serum and plasma, DNA and patient specific induced pluripotent stem cell disease modelling.
Participants with inherited retinal diseases are required to have detailed eye assessment once every 6 months for disease monitoring. Blood and skin cells are collected once for disease modelling and development of personalised treatment of retinal degeneration.
Principal Investigator – Dr Fred Chen
For more information email email@example.com
Trial registry number: ACTRN12618000738224